Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer

Jin, Chunjing; Shi, Wei; Wang, Rui; Shen, Xianjuan; Qi, Jing; Cong, Hui; Yuan, Jie; Shi, Linying; Zhu, Bingying; Luo, Xi; Zhang, Yan; Ju, Songguang

doi:10.18632/oncotarget.10107

Cited by 100 publications

(68 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, a previous report showed that a circulating lncRNA OTTHUMT00000387022 from monocytes can be used as a novel biomarker for coronary artery disease35. Circulating lncRNA-HULC may be a candidate serum tumour marker for the early diagnosis of gastric cancer and for monitoring its progression and prognosis36. LncRNA PCA3 in patient urine samples was validated as a more specific diagnostic marker for prostate cancer than the widely used prostate-specific antigen37.…”

Section: Discussionmentioning

confidence: 99%

Microarray analysis of long noncoding RNA and mRNA expression profiles in human macrophages infected with Mycobacterium tuberculosis

Yang

Wang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Macrophages play a crucial role in the control and elimination of invading Mycobacterium tuberculosis (Mtb), and also serve as the major residence for Mtb. However, the interaction between macrophages and Mtb remains to be clearly determined. Although long noncoding RNAs (lncRNAs) have emerged as key regulators in many biological processes, their roles in anti-mycobacterial responses of macrophages remain to be elucidated. Here, we applied microarray analysis to examine lncRNA and mRNA expression profiles in human primary macrophages after 72 h of infection with H37Ra or H37Rv. Our results revealed that many lncRNAs were differentially expressed in macrophages after H37Ra or H37Rv infection, indicating a possible role for lncRNAs in immune responses induced by Mtb infection and providing important cues for further functional studies. Furthermore, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) biological pathway analysis of the differentially expressed mRNAs showed the potential functions and pathways related to the pathogenesis of Mtb infection. Finally, two lncRNAs, MIR3945HG V1 and MIR3945HG V2, were identified as novel candidate diagnostic markers for tuberculosis. Our results provide novel insight into the mechanisms of the pivotal Mtb-macrophage interactions, and reveal potential targets for diagnostics and the treatment of tuberculosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Microarray analysis of long noncoding RNA and mRNA expression profiles in human macrophages infected with Mycobacterium tuberculosis

Yang

Wang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…HULC is a long non-coding RNA that has been identified as a driver of tumorigenesis in multiple cancers [37,38,39], including liver cancer, osteosarcoma, cervical cancer, pancreatic, stomach and ovarian cancers [40,41,42,43,44,45]. HULC expression is a predictor of poor prognosis across multiple cancers [46,47,48,49], and HULC silencing enhanced the effectiveness of chemotherapy in stomach cancer cell lines [44]. The involvement of HULC in the tumorigenesis of a subset of NRAS mutant melanomas appears to be unreported and merits further investigation as a possible novel discovery with therapeutic implications.…”

Section: Novel Melanoma Combinations Detected By Crsomentioning

confidence: 99%

Identifying Modules of Cooperating Cancer Drivers

Klein

Cannataro

Townsend

et al. 2020

Preprint

View full text Add to dashboard Cite

AbstractIdentifying cooperating modules of driver alterations can provide biological insights to cancer causation and would advance the development of effective personalized treatments. We present Cancer Rule-Set Optimization (CRSO) for inferring the combinations of alterations that cooperate to drive tumor formation in individual patients. Application to 19 TCGA cancer types found a mean of 11 core driver combinations per cancer, comprising 2-6 alterations per combination, and accounting for a mean of 70% of samples per cancer. CRSO departs from methods based on statistical cooccurrence, which we demonstrate is a suboptimal criterion for investigating driver cooperation. CRSO identified well-studied driver combinations that were not detected by other approaches and nominated novel combinations that correlate with clinical outcomes in multiple cancer types. Novel synergies were identified in NRAS-mutant melanomas that may be therapeutically relevant. Core driver combinations involving NFE2L2 mutations were identified in four cancer types, supporting the therapeutic potential of NRF2 pathway inhibition. CRSO is available at https://github.com/mikekleinsgit/CRSO/.

show abstract

“…Recently, Tong and colleagues reported that the plasma tumor-derived lncRNA, POU3F3, remains stable after being subjected to acid or base digestion and can serve as a biomarker for the diagnosis of esophageal squamous cell carcinoma 12. Circulating lncRNAs have also shown their prognostic potential in GC 13.…”

Section: Introductionmentioning

confidence: 99%

Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer

et al. 2017

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) can serve as blood-based biomarkers for cancer detection. To identify novel lncRNA biomarkers for gastric cancer (GC), we conducted, for the first time, genome-wide lncRNA screening analysis in two sets of samples: five paired preoperative and postoperative day 14 plasma samples from GC patients, and tissue samples from tumor and adjacent normal tissues. Candidate tumor-related lncRNAs were then quantitated and evaluated in three independent phases comprising 321 participants. The expression levels of lncRNAs were also measured in GC cell lines and the corresponding culture medium. Biomarker panels, lncRNA-based Index I and carcinoembryonic antigen (CEA)-based Index II, were constructed using logistic regression, and their diagnostic performance compared. Fagan's nomogram was plotted to facilitate clinical application. As a result, we identified five novel plasma lncRNAs (TINCR, CCAT2, AOC4P, BANCR and LINC00857), which, when combined in the lncRNA-based Index I, outperformed the CEA-based Index II (P < 0.001) and could distinguish GC patients from healthy controls with an area under the receiver-operating curve (AUC) of 0.91 (95% confidence interval (CI): 0.88-0.95). The lncRNA-based index decreased significantly by postoperative day 14 (P = 0.016), indicating its ability to monitor tumor dynamics. High values of the lncRNA-based index were correlated with tumor size (P = 0.036), depth of invasion (P = 0.025), lymphatic metastasis (P = 0.012) and more advanced tumor stages (P = 0.003). The lncRNA-based index was also able to discriminate GC patients from precancerous individuals and patients with gastrointestinal stromal tumor with AUC values of 0.82 (95% CI: 0.71-0.92) and 0.80 (95% CI: 0.68-0.91), respectively. Taken together, our findings demonstrate that this panel of five plasma lncRNAs could serve as a set of novel diagnostic biomarkers for GC detection.

show abstract

Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer

Cited by 100 publications

References 33 publications

Microarray analysis of long noncoding RNA and mRNA expression profiles in human macrophages infected with Mycobacterium tuberculosis

Microarray analysis of long noncoding RNA and mRNA expression profiles in human macrophages infected with Mycobacterium tuberculosis

Identifying Modules of Cooperating Cancer Drivers

Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer

Contact Info

Product

Resources

About